Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease
暂无分享,去创建一个
L. Dogliotti | F. Porpiglia | G. Lamanna | R. Scarpa | M. Tampellini | M. Tucci | A. Berruti | A. Mosca | C. Terrone | A. Angeli | G. Gorzegno | R. Tarabuzzi | F. Vana | Alberto Angeli | Luigi Dogliotti | Roberto Mario Scarpa | A. Berruti | C. Terrone | M. Tucci
[1] K. Weinfurt,et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] F. Saad,et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. , 2005, Journal of the National Cancer Institute.
[3] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[4] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[5] C. Pashos,et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy , 2004, Cancer.
[6] Shelby D Reed,et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. , 2004, The Journal of urology.
[7] Matthew R. Smith. Management of treatment-related osteoporosis in men with prostate cancer. , 2003, Cancer treatment reviews.
[8] P. Kantoff,et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] C. U. Uyl‐de Groot,et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. , 2003, European urology.
[10] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[11] Kevin Regan,et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Dogliotti,et al. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. , 2002, The International journal of biological markers.
[13] M. Resnick,et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. , 2002, The Journal of urology.
[14] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[15] R. DiPaola,et al. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. , 2002, The oncologist.
[16] F. Saad,et al. The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.
[17] C. Catton,et al. A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma , 2001, Cancer.
[18] L. Dogliotti,et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.
[19] D. Ferguson,et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.
[20] R. De Angelis,et al. Estimating Relative Survival of Italian Cancer Patients from Sparse Cancer Registries Data , 1997, Tumori.